Table 1 Participants’ bassline demographic and clinical characteristics
From: Clinical disease activity in autoimmune rheumatic patients receiving COVID-19 vaccines
Characteristics | Total Patients (n = 38) | SLE (n = 21) | RA (n = 17) |
|---|---|---|---|
Age, mean ± SD years | 37.4 ± 10.6 | 32.5 ± 8.9 | 43.4 ± 9.6 |
Sex | |||
Female | 34 (89.5) | 20 (58.8) | 14 (41.2) |
Male | 4 (10.5) | 1 (25.0) | 3 (75.0) |
Body Mass Index (BMI) kg/m2 | 29.7 ± 9.3 | 22.6 ± 7.5 | 33.4 ± 10.1 |
Disease Duration, mean ± SD years | 2.8 ± 0.8 | 2.8 ± 0.7 | 2.6 ± 0.8 |
Comorbidities | |||
Hypertension | 4 (10.5) | 2 (9.5) | 2 (11.8) |
Kidney disease | 2 (5.3) | 2 (9.5) | 0 (0) |
Asthma | 1 (2.6) | 1 (4.8) | 0 (0) |
Diabetes | 2 (5.3) | 0 (0) | 2 (11.8) |
Medications | |||
Prednisolone | 37 (97.4) | 21 (100) | 16 (94.1) |
Low(≤ 10 mg) | 8 (21.6) | 4 (19.0) | 4 (25.0) |
Moderate (> 10 ≤ 20 mg) | 27 (73.0) | 15 (71.4) | 12 (75.0) |
High (> 20 mg) | 2 (5.4) | 2 (9.5) | 0 (0.0) |
Hydroxychloroquine | 35 (92.1) | 21 (100) | 14 (82.4) |
Low(200 mg) | 6 (17.1) | 3 (14.3) | 3 (21.4) |
High (400 mg) | 29 (82.9) | 18 (85.7) | 11 (78.6) |
Azathioprine | 12 (31.6) | 12 (57.1) | 0 (0) |
Low (≥ 50 < 75 mg) | 4 (33.3) | 4 (33.3) | 0 (0.0) |
Moderate (≥ 75 < 100 mg) | 4 (33.3) | 4 (33.3) | 0 (0.0) |
High (≥ 100 mg) | 4 (33.3) | 4 (33.3) | 0 (0.0) |
Methotrexate | 10 (26.3) | 2 (9.5) | 8 (47.1) |
Low (≤ 7.5 mg) | 5 (50.0) | 0 (0.0) | 5 (62.5) |
Moderate (> 7.5 ≤ 15 mg) | 2 (20.0) | 0 (0.0) | 2 (25.0) |
High (> 15 mg) | 3 (30.0) | 2 (100.0) | 1 (12.5) |
Sulfasalazine | 2 (5.3) | 0 (0) | 2 (11.8) |
Mycophenolate mofetil | 2 (5.3) | 2 (9.5) | 0 (0) |
Omeprazole | 31 (81.6) | 17 (80.9) | 14 (82.3) |
Calcium | 31 (81.6) | 17 (80.9) | 14 (82.3) |
Others (e.g., folic acid) | 23 (60.5) | 8 (38.1) | 15 (88.2) |
COVID-19 Vaccines | |||
Oxford/AstraZeneca (1&2 doses) | 24 (63.2) | 14 (66.7) | 10 (58.8) |
BioNTech, Pfizer vaccine (1&2 doses) | 14 (36.8) | 7 (33.3) | 7 (41.2) |